Retriever Thrombectomy Reduced Heart Attack Infarct Size
A new trial suggests removing clots before stenting could preserve more heart muscle in patients with STEMI.
Updated on Sept. 29, 2026 in Heart Disease
Live Poll
Does evidence from new clinical trials increase your trust in the care provided by local hospitals?
The NATURE trial found that using a retriever device to remove large blood clots before standard treatment significantly reduced heart attack infarct size. This preliminary study involved 156 patients who were treated within eight hours of symptom onset.
Why it matters
Reducing infarct size is a critical goal in treating ST-elevation myocardial infarction (STEMI) because it helps preserve heart muscle function and limit long-term damage. This study explores whether mechanical clot removal can prevent the complications that occur when debris migrates into smaller vessels.
In the randomized NATURE trial of 156 patients with STEMI, the retriever thrombectomy group showed a 26% lower primary infarct size compared to those receiving conventional treatment alone. Cardiac MRI results further supported these preliminary findings with a 17% infarct size versus 28%.
The players
European Society of Cardiology
A professional medical society that promotes excellence in cardiovascular medicine and hosts major international research congresses.
NATURE Trial
A clinical research study investigating the use of retriever thrombectomy in patients with STEMI and large thrombus burden.
The details
The procedure utilizes a retriever device to physically extract a large thrombus burden prior to performing conventional balloon angioplasty and stenting. This mechanical approach is designed to prevent clot migration, where fragments of the primary blockage break off and travel into the microvasculature, potentially causing further damage to the heart muscle. By clearing the blockage first, clinicians aim to optimize blood flow through the larger coronary arteries without pushing obstructions downstream.
Timeline
Researchers presented the trial results on September 29, 2026.
Patients were treated within 8 hours of symptom onset.
Health Landscape
Current treatment standards for STEMI rely on rapid revascularization via percutaneous coronary intervention to restore blood flow. These findings presented at the European Society of Cardiology Congress offer a potential refinement to existing mechanical interventions by targeting the thrombus burden.
If you or a loved one are at risk for heart attacks, these findings highlight the importance of timely intervention to minimize heart muscle damage. While this device is not currently a universal standard, you may discuss with your cardiologist whether mechanical thrombectomy is relevant for your specific cardiac profile.
The takeaway
The NATURE trial suggests that clearing large blood clots before ballooning may protect more heart tissue during a STEMI event. Keep this development in mind as a topic to ask your physician about during routine cardiovascular health screenings.
Further reading
For more information on the latest innovations in cardiac care, visit our Heart Disease section.
Source note: This article includes information reported by Healio.
Live Poll
Does evidence from new clinical trials increase your trust in the care provided by local hospitals?
